Роль BRAF-мутацій у визначенні прогнозу папілярного раку щитоподібної залози

В. Г. Хоперія


The purpose of this multicenter study was to investigate the prognostic significance of BRAF mutations in patients with papillary thyroid carcinoma (PTC). According to the results of multiple analysis of our research, supplemented by various amounts of sample, mixed risk factors, different compositions of PTC subtypes confirmed BRAF mutation with high-risk subtypes of PTC and its role in the formation and progression of PTC. We also demonstrated the relationship of BRAF mutation recurrent PTC, even in patients at an early stage but with high tumor aggressiveness. Thus, BRAF mutation is a new prognostic marker, which complements the existing traditional prognostic factors of PTC used. Determination of BRAF mutations in thyroid aspirate needle units will conduct risk stratification of PTC in the preoperative stage. Characteristics of BRAF mutations may contribute to both primary treatment and long-term monitoring of recurrent disease in patients with PTC.

Ключові слова

BRAF mutation; thyroid cancer; prognosis; molecular marker

Повний текст:



Mercer K.E., Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target // Biochim. Biophys. Acta. – 2003. – Vol. 1653. – P. 25-40.

Hilger R.A., Scheulen M.E., Strumberg D. The RasRaf-MEK-ERK pathway in the treatment of cancer // Oncol Res Treat. – 2002. – Vol. 25. – P. 511-518.

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.,Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer // Nature. – 2002. – Vol. 417. – P. 949-954.

Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma // Cancer. Res. – 2003. – Vol. 63. – P. 1454-1457.

Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D. BRAF mutation in papillary thyroid carcinoma // J. Natl. Cancer. Inst. – 2003. – Vol. 95. – P. 625-627.

Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho T., Seruca R., Sobrinho-Simoes M. BRAF mutations and RET/ PTC rearrangements are alternative events in the etiopathogenesis of PTC // Oncogene. – 2003. – Vol. 22. – P. 4578-4580.

Xu X., Quiros R.M., Gattuso P., Ain K.B., Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines // Cancer Res. – 2003. – Vol. 63. – P. 4561-4567.

Fukushima T., Suzuki S., Mashiko M., Ohtake T., Endo Y., Takebayashi Y., Sekikawa K., Hagiwara K., Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid // Oncogene. – 2003. – Vol. 22. – P. 6455-6457.

Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers // J. Clin. Endocrinol. Metab. – 2003. – V.88. – P.4393-4397.

Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas // J. Clin. Endocrinol. Metab. – 2003. – Vol. 88. – P. 5399-5404.

Cohen Y., Rosenbaum E., Clark D.P., Zeiger M.A., Umbricht C.B., Tufano R.P., Sidransky D., Westra W.H. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules // Clin. Cancer. Res. – 2004. – Vol. 10. – P. 2761-2765.

Xing M., Vasko V., Tallini G., Larin A., Wu G., Udelsman R., Ringel M.D., Ladenson P.W., Sidransky D. BRAF T1796A transversion mutation in various thyroid neoplasms // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89. – P. 1365-1368.

Xing M., Tufano R.P., Tufaro A.P., Basaria S., Ewertz M., Rosenbaum E., Byrne P.J., Wang J., Sidransky D., Ladenson P.W. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89. – P. 2867-2872.

Xing M., Cohen Y., Mambo E., Tallini G., Udelsman R., Ladenson P.W., Sidransky D. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis // Cancer Res. – 2004. – Vol. 64. – P. 1664-1668.

Trovisco V., Vieira de Castro I., Soares P., Maximo V., Silva P., Magalhaes J., Abrosimov A., Guiu X.M., Sobrinho-Simoes M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma // J. Pathol. – 2004. – Vol. 202. – P. 247-251.

Puxeddu E., Moretti S., Elisei R., Romei C., Pascucci R., Martinelli M., Marino C., Avenia N., Rossi E.D., Fadda G., Cavaliere A., Ribacchi R., Falorni A., Pontecorvi A., Pacini F., Pinchera A., Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89. – P. 2414-2420.

Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., Westra W.H. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment // Mod. Pathol. – 2004. – Vol. 17. – P. 1359-1363.

Kim K.H., Kang D.W., Kim S.H., Seong I.O., Kang D.Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population // Yonsei Med. J. – 2004. – Vol. 45. – P. 818-821.

Fugazzola L., Mannavola D., Cirello V., Vannucchi G., Muzza M., Vicentini L., Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers / / Clin. Endocrinol. (Oxf). – 2004. – Vol. 61. – P. 239-243.

Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 // Cancer. – 1998. – Vol. 83. – P. 2638-2648.<2638::aid-cncr31>;2-1

Paterson I.C., Greenlee R., Adams Jones D. Thyroid cancer in Wales 1985-1996: a cancer registry-based study // Clin. Oncol. (R Coll Radiol). – 1999. – Vol.11. – P. 245-251.

Hay I.D., Bergstralh E.J., Goellner J.R., Ebersold J.R., Grant C.S. Predictingoutcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 // Surgery. – 1993. – Vol. 114. – P. 1050-1057.

Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer // Am. J. Med. – 1994. – Vol. 97. – P. 418-428.

Fonseca E., Soares P., Rossi S., Sobrinho-Simoes M. Prognostic factors in thyroid carcinomas // Verh. Dtsch. Ges. Pathol. – 1997. – Vol. 81. – P. 82-96.

Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991 // Cancer. – 1997. – Vol. 79. – P. 564-573.<564::aid-cncr20>;2-0

Sherman S.I., Brierley J.D., Sperling M., Ain K.B., Bigos S.T., Cooper D.S., Haugen B.R., Ho M., Klein I., Ladenson P.W., Robbins J., Ross D.S., Specker B., Taylor T., Maxon H.R. 3rd Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group // Cancer. – 1998. – Vol. 83. – P. 1012-1021.<1012::aid-cncr28>;2-9

LiVolsi V.A., Fadda G., Baloch Z.W. Prognostic factors in well-differentiated thyroid cancer // Rays. – 2000. – Vol. 25. – P. 163-175.

Xing M., Usadel H., Cohen Y., Tokumaru Y., Guo Z., Westra W.B., Tong B.C., Tallini G., Udelsman R., Califano J.A., Ladenson P.W., Sidransky D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing / / Cancer Res. – 2003. – Vol. 63. – P. 2316-2321.

Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations // J. Am. Stat. Assoc. – 1958. – Vol. 53. – P. 457-481.

Cox D.R. Regression models and life tables (with discussion) // J. R. Stat. Soc. B. – 1972. – Vol. 34. – P. 187-220.

Hay I.D., Grant C.S., Bergstralh E.J., Thompson G.B., van Heerden J.A., Goellner J.R. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? // Surgery. – 1998. – Vol. 124. – P. 958-964.

Salvatore G., Giannini R., Faviana P., Caleo A., Migliaccio I., Fagin J.A., Nikiforov Y.E., Troncone G., Palombini L., Basolo F., Santoro M. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. – 2004. – Vol. 10. – P. 5175-5180.

Xing M. BRAF mutation in thyroid cancer // Endocr. Relat. Cancer. – 2005. – Vol. 12. – P. 245-262.

Porra V., Ferraro-Peyret C., Durand C., SelmiRuby S., Giroud H., Berger-Dutrieux N., Decaussin M., Peix J.L., Bournaud C., Orgiazzi J., Borson-Chazot F., Dante R., Rousset B. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas // J. Clin. Endocrinol. Metab. – 2005. – Vol. 90. – P. 3028-3035.

Giordano T.J., Kuick R., Thomas D.G., Misek D.E., Vinco M., Sanders D., Zhu Z., Ciampi R., Roh M., Shedden K., Gauger P., Doherty G., Thompson N.W., Hanash S., Koenig R.J., Nikiforov Y.E. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis // Oncogene. – 2005. – Vol. 24(44). – P. 6646-6656.

Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.H., Refetoff S., Nikiforov Y.E., Fagin J.A. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation // Cancer. Res. – 2005. – Vol. 65. – P. 4238-4245.

Trovisco V., Soares P., Preto A., de Castro I.V., Lima J., Castro P., Maximo V., Botelho T., Moreira S., Meireles A.M., Magalhaes J., Abrosimov A., Cameselle-Teijeiro J., Sobrinho-Simoes M. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness // Virchows Arch. – 2005. – Vol. 446. – P. 589-595.

Пристатейна бібліографія ГОСТ

Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter